Looking ahead to the pivotal trial in triple-negative breast cancer (TNBC) with IMMU-132, slated to begin this summer, Immunomedics Inc. stands as "the only game in town at the moment this far along that has an antibody that targets this [TROP-2] receptor," Chau Cheng, director of investor relations, told BioWorld Today.